Retatrutide
Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist studied in metabolic research.
Volume discounts up to 35% off — buy more, save more.
Volume Pricing
Research use only. Not for human or veterinary use. Not FDA approved. Supplied as lyophilized powder in a sterile vial for in-vitro laboratory research by qualified professionals.
About Retatrutide
Retatrutide, also designated LY3437943, is a single-molecule synthetic peptide engineered to act simultaneously at three incretin and energy-balance targets: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. This triple-agonist design distinguishes it from earlier single- and dual-receptor peptides and is the focus of considerable preclinical and clinical investigation into integrated metabolic signaling.
In research contexts, retatrutide is examined for its effects on glucose handling, energy expenditure, lipid metabolism, and body-composition models. It is supplied as a lyophilized powder intended for reconstitution in suitable solvent under laboratory conditions, with ≥98% purity confirmed by analytical testing and a certificate of analysis available on request. Sold strictly for research use only.
What Is Retatrutide (LY3437943)?
Retatrutide (INN: LY3437943, CAS: 2381272-89-3) is an investigational triple incretin receptor agonist developed by Eli Lilly. It is the first peptide in its class to simultaneously target three receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide), the GLP-1 receptor (glucagon-like peptide-1), and the glucagon receptor.
This triple-receptor mechanism distinguishes Retatrutide from earlier-generation compounds. Semaglutide activates only GLP-1 receptors; tirzepatide activates both GLP-1 and GIP receptors. Retatrutide's additional glucagon receptor agonism adds a third dimension to its metabolic research profile, making it the subject of active Phase 3 clinical investigation.
Our Retatrutide is supplied as lyophilized powder in a sterile vial, tested at ≥98% purity by HPLC with mass spectrometry identity confirmation. A Certificate of Analysis (CoA) is available for every batch. For in-vitro research and laboratory use only. Not for human consumption.
Retatrutide — Frequently Asked Questions
What is Retatrutide?
Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist studied in metabolic research.
What purity is Retatrutide, and is a certificate of analysis available?
Retatrutide is supplied at ≥98% purity, verified by HPLC. A certificate of analysis (COA) is available on request so researchers can confirm identity and purity before use.
How is Retatrutide supplied and stored?
Retatrutide ships as a lyophilized (freeze-dried) powder in a sterile vial. Store the lyophilized powder cold and away from light; once reconstituted for research it should be refrigerated and handled per standard peptide-stability practice.
What quantities of Retatrutide are available and what does it cost?
Retatrutide is offered in 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg. Pricing starts at $80.00 per vial, with volume discounts of up to 35% off on larger quantities and free US shipping on every order.
Is Retatrutide for human use?
No. Retatrutide is sold strictly for in-vitro laboratory research use only by qualified professionals. It is not for human or veterinary use and is not approved by the FDA for any therapeutic use.
How do I order and pay for Retatrutide?
Add Retatrutide to your cart and check out on the site. Payment is by Bitcoin (BTC); orders ship from the US within 1–2 business days of confirmed payment. New to Bitcoin? A 5-minute Cash App guide is linked at checkout.